Malaysia Country Commercial Guide
Learn about the market conditions, opportunities, regulations, and business conditions in Malaysia, prepared by at U.S. Embassies worldwide by Commerce Department, State Department and other U.S. agencies’ professionals.
Select Country Guide
Healthcare
Last published date:

Market Overview

According to BMI Fitch Solutions, Malaysia’s healthcare expenditure is projected to grow at a compound annual growth rate (CAGR) of 8.7% between 2023 and 2028. The government continues to expand public healthcare capacity, as demonstrated by the 2025 national budget, which allocated $10.1 billion to the Ministry of Health (MOH)—a significant increase from $9.2 billion in 2024.

With 11.6% of the population over age 60 and a high burden of non-communicable diseases (NCDs)—notably diabetes, which affects roughly 1 in 5 Malaysian adults—the country faces growing healthcare challenges. The dual public-private system addresses these issues differently:
•    Private providers are leading the adoption of health technology and international partnerships to attract medical travelers.
•    Public providers are expanding preventive services and rural access, driving demand for technology and equipment.

Over the next decade, Malaysia is expected to prioritize:
•    High-tech medical devices
•    Health IT and digital health
•    Elder care services
•    NCD monitoring and management
•    Medical travel and clinical research

U.S. exporters typically enter the market through authorized distributors or by establishing a local subsidiary.
 

Opportunities

Non-communicable diseases (NCDs)

The government’s Healthy Malaysia program promotes wellness and early detection. U.S. companies offering consumer medical devices, diagnostics, and elder care solutions are well-positioned.

Medical devices

Malaysia is a major exporter of low-tech medical supplies but imports 88% of its high-tech medical devices. Opportunities exist in:
•    Diagnostic imaging
•    Surgical and dental instruments
•    Orthopedic and prosthetic devices
•    Wearables and at-home health monitoring

Health technology

Malaysia’s Health White Paper envisions a digital transformation in care delivery. The MOH ICT Masterplan outlines expansion in:
•    Telemedicine
•    Electronic medical records (EMR)
•    Data privacy and cybersecurity

Medical travel

Malaysia aims to be a regional leader in specialized care, attracting travellers from across Southeast Asia, South Asia, and the Middle East.  Private hospitals are investing in robotic surgey and advanced technology to draw medical tourists. The country will continue to promote its branding as:
•    Fertility Hub of Asia
•    Cardiology Hub of Asia
•    Center of Excellence for Cancer care

Clinical research

Malaysia’s multi-ethnic population offers diverse genetic representation, making it a valuable site for clinical research in:
•    Infectious diseases
•    Oncology
•    Cardiology
•    Hematology

U.S. firms can form partnerships with hospitals and research institutions for joint trials.

Trade Events

APHM International Healthcare Conference & Exhibition 2025: June 9-11, 2025 
Lab Asia 2025: July 14-16, 2025
Malaysia International Healthcare (MIH) Megatrends 2025: October/ November 2025
International Medical Device Exhibition & Conference (IMDEC): August 2026

Resources of Malaysian Government Authorities

×

Global Business Navigator Chatbot Beta

Welcome to the Global Business Navigator, an artificial intelligence (AI) Chatbot from the International Trade Administration (ITA). This tool, currently in beta version testing, is designed to provide general information on the exporting process and the resources available to assist new and experienced U.S. exporters. The Chatbot, developed using Microsoft’s Azure AI services, is trained on ITA’s export-related content and aims to quickly get users the information they need. The Chatbot is intended to make the benefits of exporting more accessible by understanding non-expert language, idiomatic expressions, and foreign languages.

Limitations

As a beta product, the Chatbot is currently being tested and its responses may occasionally produce inaccurate or incomplete information. The Chatbot is trained to decline out of scope or inappropriate requests. The Chatbot’s knowledge is limited to the public information on the Export Solutions web pages of Trade.gov, which covers a wide range of topics on exporting. While it cannot provide responses specific to a company’s product or a specific foreign market, its reference pages will guide you to other relevant government resources and market research. Always double-check the Chatbot’s responses using the provided references or by visiting the Export Solutions web pages on Trade.gov. Do not use its responses as legal or professional advice. Inaccurate advice from the Chatbot would not be a defense to violating any export rules or regulations.

Privacy

The Chatbot does not collect information about users and does not use the contents of users’ chat history to learn new information. All feedback is anonymous. Please do not enter personally identifiable information (PII), sensitive, or proprietary information into the Chatbot. Your conversations will not be connected to other interactions or accounts with ITA. Conversations with the Chatbot may be reviewed to help ITA improve the tool and address harmful, illegal, or otherwise inappropriate questions.

Translation

The Chatbot supports a wide range of languages. Because the Chatbot is trained in English and responses are translated, you should verify the translation. For example, the Chatbot may have difficulty with acronyms, abbreviations, and nuances in a language other than English.

Privacy Program | Information Quality Guidelines | Accessibility